


Financial Tear Sheet

Aduro is a clinical-stage cancer immunotherapy company with three products currently in human trials. The company's lead candidate – an immunotherapy regimen combining our proprietary CRS-207 with GVAX Pancreas – is targeting metastatic pancreatic cancer and has received Breakthrough Therapy designation from the US Food and Drug Administration.

Stock Quote

ADRO (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$8.18
Change (%)	- 0.03 (0.24%)
Volume	132,014
Data as of December 18, 2017 2:02 p.m. ET	
Minimum 20 minute delay	
Refresh quote	

Stock Chart



Press Releases

December 18, 2017

Aduro Biotech Announces the Initiation of a Phase 1/2 Clinical Trial of BION-1301, a Novel Anti-APRIL Antibody, for the Treatment of Multiple Myeloma

December 12, 2017

Aduro Biotech Provides Update on CRS-207 Programs

Events & Presentations

There are currently no events scheduled.

Data Provided by Thomson Reuters